Clinical Trials Browser

Phase 1/2 × Lung Neoplasms × anlotinib × Clear all

NCT03983928 2019-08-15

Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer

Phase 1/2 Unknown

Lung Neoplasms